Not yet recruiting
Relacorilant and Nab-Paclitaxel in Recurrent or Metastatic Cervical Cancer
NCT07763496· Phase 2· ARCAGY/ GINECO GROUP· Source
Contact: Antoine Angelergues, MD
Not yet recruiting
Topical Clobetasol Propionate for Inflammatory Hand Osteoarthritis
NCT07812701· Phase 2· Assistance Publique - Hôpitaux de Paris· Source
Recruiting
Personalizing chemotherapy selection after surgery for patients with stage III colorectal cancer using a blood test
2025-521045-24-00· Phase 3· Unicancer· Source
Recruiting
A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer
NCT07673887· Phase 3· Astellas Pharma Global Development, Inc.· Source
Not yet recruiting
Liver-directed Chemotherapy After Surgery of Liver Metastases of Colorectal Cancer in Patients With High Risk of Recurrence of Their Disease
NCT07284394· Phase 3· UNICANCER· Source
Recruiting
A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizumab in Combination with FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer (HARMONi-GI3)
2025-521587-35-00· Phase 3· Summit Therapeutics Inc.· Source
Not yet recruiting
Bosentan in the Treatment of Giant Cell Arteritis
NCT06957002· Phase 2· Assistance Publique - Hôpitaux de Paris· Source
Recruiting
Prospective National Cohort Evaluating Prognostic Factors for Efficacy of Fruquintinib Treatment in Patients With Metastatic Colorectal Cancer
NCT07124858· Federation Francophone de Cancerologie Digestive· Source
Contact: OLIVIER DUBREUIL
Not yet recruiting
Multicenter, randomized, double-blinded, placebo-controlled phase 3 trial to evaluate nonavalent HPV vaccine as a secondary prevention in patients treated for human papilloma virus related high-grade squamous intraepithelial lesions.(BioHPV)
2024-520140-42-00· Phase 3· Institut Gustave Roussy· Source
Recruiting
Total Knee Arthroplasty With Personalized Implantation: Computer Navigation-Assisted Surgery Versus Robotic-Assisted Surgery
NCT07574762· Groupe Hospitalier Diaconesses Croix Saint-Simon· Source
Contact: Younes KERROUMI, Clinical Research Physician
Not yet recruiting
Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer
NCT07150403· Phase 2· Federation Francophone de Cancerologie Digestive· Source
Recruiting
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
NCT07213804· Phase 3· Eli Lilly and Company· Source
Contact: Antoine Angelergues (principal investigator)
Active, not recruiting
Stability of Distal Tibiofibular Syndesmosis With or Without Fixation of Posterior Fragments in Bimalleolar Fractures
NCT07755462· Groupe Hospitalier Diaconesses Croix Saint-Simon· Source
Recruiting
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
NCT06952803· Phase 3· AstraZeneca· Source
Recruiting
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
NCT07044336· Phase 3· AstraZeneca· Source
Recruiting
Detecting Tumor DNA in the Blood of HR+/HER2-low Metastatic Breast Cancer Patients to Find Candidates for T-DXd Therapy
NCT06680596· Phase 2· UNICANCER· Source
Recruiting
Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer
NCT06606730· Phase 3· UNICANCER· Source
Active, not recruiting
Phase 2 Pan-Tumor Trial of R-DXd for Advanced/Metastatic Solid Tumors
NCT06660654· Phase 2· Daiichi Sankyo Inc.· Source
Recruiting
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
NCT06952504· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
National Multicentre Study of the Natural History of Acid Sphingo-myelinase Deficiency in Adults and Children
NCT06985212· Wladimir MAUHIN, Dr· Source
Contact: Djazia BOUZELMAT, Clinical Research Assistant
Recruiting
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
NCT06824467· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
NCT06989112· Phase 3· AstraZeneca· Source
Recruiting
Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer
NCT06245356· Phase 2· UNICANCER· Source
Recruiting
PRODIGE 90 - FFCD 22024 - PREDIR-NEOREC - Neoadjuvant dostarlimab with short course radiotherapy in a watch-and-wait strategy for microsatellite unstable or mismatch repair-deficient locally advanced rectal cancer patients: a randomized phase II trial
2024-510772-20-00· Phase 2· Centre Hospitalier Universitaire De Dijon· Source
Active, not recruiting
A MULTICENTER, SEEKING SIGNAL, RANDOMISED, OPEN-LABEL PHASE II OF RELATLIMAB AND NIVOLUMAB VS NIVOLUMAB ALONE IN LOCALLY ADVANCED CERVICAL CANCERS
NCT06715241· Phase 2· ARCAGY/ GINECO GROUP· Source
Recruiting
Study of the Quality of Life of Patients With Fabry Disease Aged 65 and Over With and Without Specific Treatment
NCT07277361· Wladimir MAUHIN, Dr· Source
Contact: Djazia BOUZELMAT, Clinical Research Assistant
Recruiting
Study on the Relative Dose Intensity of PARP Inhibitors in Real-life on a Population of Patients Over 70 Years With Advanced Ovarian Cancer
NCT06572735· Hospices Civils de Lyon· Source
Contact: Hadiya Dr TARIQ, MD
Active, not recruiting
Treatment of microstellite stable metastatic colorectal cancer presenting high immune infiltrate with chemotherapy (XELOX or FOLFOX Bevacizumab) and
immunotherapy ( Pembrolizumab)
NCT04262687· Phase 2· Fondation Franc.Cancerologie Digestive· Source
Recruiting
Utility of Adjusting Chemotherapy Dose & Dosing Schedule With the SALVage Weekly Dose-dense Regimen in Patients With Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery
NCT06476184· Phase 3· ARCAGY/ GINECO GROUP· Source
Contact: Frédéric SELLE
Active, not recruiting
A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression
NCT06365853· Phase 2· AbbVie· Source
Active, not recruiting
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
NCT06459180· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
Personalized Medicine for Advanced Biliary Cancer Patients
NCT05615818· Phase 3· UNICANCER· Source
Contact: Olivier DUBREUIL, MD
Recruiting
Neoadjuvant Chemotherapy for Obstructive Colon cancER First Treated by cOlostomy
NCT06107920· Phase 3· University Hospital, Rouen· Source
Recruiting
First-line EXL01 With Nivolumab and FOLFOX for PD-L1 CPS ≥5 Metastatic Gastric Cancer
NCT06253611· Phase 2· GERCOR - Multidisciplinary Oncology Cooperative Group· Source
Contact: Olivier DUBREUIL, MD
Active, not recruiting
Customized Knee Arthroplasty With or Without Posterior Cruciate Ligament Retention: A CR-PS Approach
NCT07757581· Groupe Hospitalier Diaconesses Croix Saint-Simon· Source
Recruiting
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT06161025· Phase 2/3· Daiichi Sankyo· Source
Active, not recruiting
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
NCT06132958· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
Abemaciclib and Letrozole in Patients With Estrogen Receptor-positive Rare Ovarian Cancer
NCT05872204· Phase 2· Universitaire Ziekenhuizen KU Leuven· Source
Active, not recruiting
Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer
NCT05476796· Phase 2· UNICANCER· Source
Active, not recruiting
A study to test trimodulin in adult hospitalized patients with severe pneumonia
2022-501352-28-00· Phase 3· Biotest GmbH & Co. KGaA· Source
Active, not recruiting
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
NCT05714202· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
Study of General Foetal Movements Using Ultrasound
NCT07868185· François FARGES· Source
Contact: Djazia BOUZELMAT, Clinical Research Assistant
Recruiting
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
NCT05640999· Phase 2· Canadian Cancer Trials Group· Source
Contact: Frederic Selle
Active, not recruiting
Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer
NCT05425940· Phase 3· Exelixis· Source
Recruiting
ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)
NCT04916613· Phase 3· UNICANCER· Source
Active, not recruiting
Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line
NCT05201547· Phase 3· ARCAGY/ GINECO GROUP· Source
Recruiting
Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian Cancer
NCT05183984· Phase 2· ARCAGY/ GINECO GROUP· Source
Active, not recruiting
MSI/dMMR tumors in perioperative setting
NCT04795661· Phase 2· Centre Leon Berard· Source
Recruiting
TALazoparib and Avelumab as Maintenance Therapy in Platinum-Sensitive Metastatic or Locally Advanced URothelial Carcinoma
NCT04678362· Phase 2· Centre Francois Baclesse· Source
Active, not recruiting
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
NCT04700124· Phase 3· Merck Sharp & Dohme LLC· Source
Showing 50 of 64.